Untapped obesity market BST targets a large global market of obesity, metabolic syndrome, and type 2 diabetes through minimally invasive endoscopic visceral lipectomy devices, presenting a potential opportunity to partner with hospitals, obesity clinics, and bariatric centers seeking safer alternatives to traditional bariatric surgery.

Early stage funding With revenue under one million and initial funding of 475k, BST is a high-growth, pre-IPO company likely seeking strategic investment, licensing, or collaboration deals to accelerate R&D, manufacturing scale, and regulatory pathways.

IP driven moat Recent U.S. patent grants and European patent application for endoscopic fat removal methods indicate a defensible technology position; potential sales angles include licensing opportunities, co-development with device manufacturers, and exclusive distribution rights.

Bespoke device focus BST’s emphasis on adipose tissue handling across liposuction, fat grafting, and adipocyte-derived stem cell processing opens cross-sell avenues with plastic/reconstructive surgeons, bariatric programs, and regenerative medicine labs seeking integrated solutions.

Strategic industry fit As a medical equipment manufacturer with a global obesity burden, BST aligns with large medical device players and contract manufacturers for joint development, distribution partnerships, or acquisition talks to accelerate market access and scale.